Dr. Reddy’s Laboratories announces the launch of Paricalcitol Injection in the U.S. Market

Dr. Reddy’s Laboratories Ltd announced today that it has launched Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar (paricalcitol) Injection in the United States market approved by the U.S. Food & Drug dr-reddy-paricalcitol-injectionAdministration (USFDA).

The Zemplar brand and generic had U.S. sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.

Dr. Reddy’s Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA   product launched in the US market.

Zemplar is a registered trademark of ABBVIE Inc.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top